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Abstract 
The effect of β-blockers in ST-elevation myocardial infarction (STEMI) patients who have undergone primary 
percutaneous coronary intervention (PCI) has not been adequately evaluated. Using a large multi-center registry in Japan, 
we identified 3,692 patients who underwent PCI within 24 hours from onset of STEMI and were discharged alive from 
2005 to 2007. Three-year cardiovascular outcomes were compared between the 2 groups of patients with (N = 1,614) or 
without (N = 2,078) β-blocker prescription at discharge. Compared with patients in the no-β group, patients in the β 
group were younger, more frequently male, more often had hypertension and atrial fibrillation but less often had chronic 
obstructive pulmonary disease than in the no-β group. Statins and angiotensin-converting enzyme inhibitors /angiotensin 
receptor blockers were more frequently prescribed in the β group. Crude incidence of cardiac death and/or recurrent 
myocardial infarction (cardiac death/MI) tended to be higher in the β group (7.6% vs. 6.2%, log-rank p = 0.1). After 
adjusting for potential confounders, β-blockers were associated with significantly higher risk for cardiac death/MI 
(hazard ratio 1.43, 95% confidence interval: 1.06-1.94, p = 0.01). Beta-blocker prescription at discharge was not 
associated with better cardiovascular outcomes in patients who underwent PCI after STEMI. Large-scale randomized 
controlled trials are needed to evaluate the role of β-blocker therapy in these patients. 
Key Words:  Beta-blocker, myocardial infarction, percutaneous coronary intervention, prognosis 
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Introduction 
The current clinical guidelines for treatment of ST-segment elevation acute myocardial infarction (STEMI) recommend 
administration of oral β-blockers indefinitely to patients who have no contraindications. 1,2 The guidelines were 
established on the basis of results from studies conducted in the pre-fibrinolytic era or from studies including a relatively 
small proportion of patients with early revascularization by thrombolytic therapy or percutaneous coronary intervention 
(PCI). 3,4 However, conclusions from observational studies in patients treated with PCI after STEMI were discordant 
regarding the efficacy of oral β-blocker therapy. 5,6 In the Primary Angioplasty in Acute Myocardial Infarction (PAMI) 
study, it was reported that β-blockers after PCI were associated with lower 6-month mortality in patients with acute 
myocardial infarction (AMI). 5 In contrast, in the j-Cypher study, β-blockers were not associated with 3-year mortality in 
patients who underwent PCI after STEMI and survived the index hospitalization. 6 However, the sample sizes were 
relatively small and neither the types nor the doses of β-blockers were known in the previous studies. Therefore, the 
present study was designed to examine whether prescription of β-blockers at discharge was independently associated 
with improved cardiovascular outcomes in patients who underwent PCI after STEMI using a recent large registry in 
Japan. 
Methods 
The Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) AMI registry is a 
physician-initiated non-company sponsored multi-center registry that enrolled consecutive AMI patients undergoing 
coronary revascularization within 7 days of the symptom onset between January 2005 and December 2007 across 26 
tertiary hospitals in Japan (Supplemental Appendix A). Among 5,429 patients enrolled in the registry, 4,444 patients 
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were diagnosed as STEMI. Excluding 494 patients who underwent PCI beyond 24 hours and 258 patients who died 
during the index hospitalization, the current study population consisted of 3,692 patients who underwent PCI within 24 
hours from onset of STEMI and survived the index hospitalization (Figure 1). Demographics, clinical factors, 
angiographic data, and discharge medications were collected from hospital charts or hospital databases according to 
pre-specified definitions by experienced clinical research coordinators (Supplemental Appendix B). Follow-up data were 
obtained from hospital charts or by contacting patients or referring physicians through 3 years. The relevant review 
boards or ethics committees in all 26 participating centers approved the study protocol.  
Definitions 
Prior myocardial infarction (MI), heart failure (HF), hypertension, current smoking, atrial fibrillation, chronic 
obstructive lung disease (COPD), liver cirrhosis, and malignancy were regarded as present when these diagnoses were 
recorded in the hospital charts. Prior stroke was defined as infarction or intracranial bleeding with neurological 
symptoms lasting > 24 hours. Peripheral vascular disease was regarded to be present when carotid, aortic, or other 
peripheral vascular diseases were being treated or scheduled for surgical or endovascular interventions. Left ventricular 
ejection fraction (LVEF) was measured either by contrast left ventriculography or by echocardiography within 3 months 
after PCI and low LVEF was defined as LVEF ≤ 40%.  
During the follow-up, death was regarded as cardiac in origin unless obvious non-cardiac causes could be identified. 
MI was defined according to the definition in the Arterial Revascularization Therapy Study. 7 Events such as cardiac 
death and MI were adjudicated by a clinical event committee. Hospitalization for HF was defined as hospitalization due 
to worsening HF requiring intravenous drug therapy. The primary outcome measure for the current analyses was a 
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composite endpoint of cardiac death and recurrent MI (cardiac death/MI). The secondary outcome measures assessed 
included all-cause death, cardiac death, recurrent MI, and hospitalization for HF.  
Statistical methods 
Cumulative incidences of clinical event rates were estimated by the Kaplan-Meier method and differences were 
assessed with the log-rank test. We used multivariable Cox proportional-hazards model stratified by centers to estimate 
the hazard ratio (HR) of β-blocker therapy at discharge for primary and secondary outcome measures by incorporating 
β-blocker therapy together with clinically relevant risk-adjusting variables. Adjusted HR and their 95% confidence 
interval (CI) were calculated. We computed adjusted cumulative incidence curves of β group and no-β group using the 
multivariable Cox proportional-hazards model in conjunction with methods described by Ghali et al. 8,9 The associations 
between β-blocker therapy at discharge and cardiovascular outcomes in the subgroup of patients with preserved and low 
LVEF were analyzed in the same way. We also performed subgroup analyses of different types and doses of β-blockers 
among patients in the β group. 
Because clinical factors related to treatment selection may be expected to confound the rate of cardiovascular 
outcomes, we performed a propensity score-matched analysis between the β and no-β groups as a sensitivity analysis. 
Logistic regression was used to calculate the propensity score of prescription of β-blockers using clinically relevant 
variables and center. Patients in the β group were randomly matched to patients in the no-β group using a greedy 
matching strategy. 10 Survival analysis comparing the cases and controls was conducted using the Kaplan-Meier method, 
and statistical comparisons were drawn using the log-rank test. 
All analyses were conducted by physicians (B.B. and N.O.) and a statistician (T.M.) using JMP 8 and SAS 9.2 (SAS 
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Institute Inc., Cary, NC), and all the reported p values were two-sided. A p value < 0.05 was regarded as statistically 
significant. 
Results 
Among the total of 3,692 study patients, oral β-blockers were prescribed in 1,614 patients (β group, 43.7%) at 
hospital discharge, while 2,078 patients were not (no-β group, 56.3%) (Figure 1). There were significant differences in 
baseline characteristics between the β and no-β groups (Table 1). Patients in the β group were younger, more frequently 
male, and more often had hypertension, high body weight, high body mass index (BMI), anterior MI, atrial fibrillation, 
and target of proximal left anterior descending artery. COPD were less prevalent in the β group. Statins, 
angiotensin-converting enzyme inhibitors (ACE-I) /angiotensin receptor blockers, and warfarin were more frequently 
prescribed in the β group (Table 1).  
Clinical outcomes 
Median follow-up duration was 955 (IQR: 693-1,248) days. Clinical follow-up were completed in 93.6% at 1 year, 
and 87.2% at 2 years. Three-year incidence of cardiac death/MI was 6.6% for the entire study population. Crude 3-year 
incidence of cardiac death/MI was not significantly different between patients in the β group and those in the no-β group 
(7.6% vs. 6.2%, log-rank p = 0.11, Table 2 and Figure 2A). However, after adjusting for 39 potential confounders listed 
in Table 1, the risk for cardiac death/MI was significantly higher in the β group (adjusted HR 1.43, 95% CI: 1.06-1.94, p 
= 0.01, Supplemental Table 1 and Figure 2A). The risk for hospitalization for HF was also significantly higher in the β 
group, however, the risk for all-cause death was not different between the groups (Table 2). 
Subgroup analyses 
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In 2,944 patients with LVEF data, 2,494 patients (84.7%) had preserved LVEF at baseline. The differences in 
baseline characteristics between the β and no-β groups in the preserved- and low- LVEF subgroups were similar to the 
differences in the entire study population (Supplemental Tables 2 and 3). After adjusting for confounding variables, the 
incidence of cardiac death/MI was higher in the β group both in the preserved-LVEF subgroup (adjusted HR 1.27, 95% 
CI: 0.87-1.86, p = 0.21) and in the low-LVEF subgroup (adjusted HR 1.75, 95% CI: 0.69-4.47, p = 0.24), although the 
differences were not statistically significant (Table 2, Figures 2B and 2C).  
Types and doses of β-blockers 
Among 1,614 patients in the β group, carvedilol was prescribed in 1,456 patients (90.2%). The median dose of 
carvedilol in the current study population was 5 (range: 0.25-60.0) mg per day. Among 1,456 patients with carvedilol, 
385 (26.5%) received carvedilol ≥ 10 mg per day, while 1,071 (73.6%) received < 10 mg per day (Supplemental Table 4). 
Crude incidence of 3-year cardiac death/MI was significantly lower in patients who received carvedilol ≥ 10 mg per day 
than in patients who received carvedilol < 10 mg per day (4.7% vs. 8.9%, log-rank p = 0.02, Supplemental Table 5). 
However, after adjusting for clinically relevant risk-adjusting variables, the risk for cardiac death/MI was not 
significantly different (adjusted HR 0.65, 95% CI: 0.38-1.05, p = 0.08, Supplemental Table 5).  
Sensitivity Analyses 
Propensity score of prescription of β-blockers was calculated using 24 clinically relevant variables (listed in 
Supplemental Table 6). In the propensity-score matched model, no significant differences in the baseline characteristics 
were found between the β and no-β groups, except that patients in the β group more frequently had prior HF and shock at 
presentation (Supplemental Table 6). There was no significant difference in the 3-year incidence of cardiac death/MI 
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between the β and no-β groups in this model (7.6% vs. 6.1%, log-rank p = 0.2, Supplemental Table 7). However, more 
hospitalizations for HF were observed in the β-group (7.2% vs. 3.9%, log-rank p < 0.0001) (Supplemental Table 7). 
Discussion 
The major findings of this recent registry analyses were as follows: (1) the 3-year cardiovascular event rate of 
patients who underwent PCI after STEMI was relatively low; (2) β-blocker prescription at discharge was not associated 
with better cardiovascular outcomes in these patients. 
Despite the recommendations of the clinical guidelines, β-blocker use in STEMI has been less prevalent in the 
real-world clinical practice. 11 In the current study population, only 43.7% of patients received oral β-blocker therapy at 
discharge. That was less than the frequencies of β-blocker prescription reported from the PAMI study conducted in the 
USA (68.0%), 5 but similar to the rate reported in the Heart Institute of Japan Acute Myocardial Infarction registry 
(HIJAMI) study (32.2%) and the j-Cypher study (38.4%) conducted in Japan. 6,12  
The main mechanisms of the beneficial effects of β-blockers in patients with STEMI are considered to be the 
prevention of the cardiotoxic effects of catecholamines and the attenuation of the myocardial oxygen demand. β-blockers 
are also thought to be effective in reducing tachyarrhythmic events. Previous studies conducted in the pre-PCI era 
showed markedly lower mortality rate with β-blocker therapy in STEMI patients. 3,4 However, in the present study, 
relatively low 3-year cardiovascular event rate was observed despite the low prescription rate of β-blockers at discharge. 
In addition to the preserved LVEF in most STEMI patients who have undergone emergent PCI, the high use of up-to-date 
medications such as ACE-I /angiotensin receptor blockers and statins may result in the improved clinical outcomes of 
these patients. On the other hand, the adverse effects of β-blockers such as coronary spasm should be considered in these 
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patients as they are disadvantageous. In the Japanese β-blocker and Calcium Antagonist Myocardial Infarction (JBCMI) 
study, the incidence of coronary spasm was significantly higher in patients with β-blocker therapy than those with 
calcium antagonist therapy (1.2% vs. 0.2%, p = 0.02), but no significant difference was observed in cardiac mortality 
(1.7% vs. 1.1%, p = 0.37). 13 It’s important to note that a majority of STEMI patients have hypertension (85.9% of 
patients in the β group had hypertension in the present study) and the adverse effects of β-blockers have been a concern 
in patients with hypertension on the basis of recent clinical trials. 14-16 
Study limitations 
Our study has several important limitations. First, 90.2% of the β-blockers prescribed were carvedilol in the present 
study. The impacts of different types of β-blockers on clinical outcomes were difficult to compare. However, carvedilol, 
a nonselective β-blocker with alpha 1-adrenergic receptor blocking and antioxidant effects, has been reported to have 
superior cardioprotective effects compared to other β-blockers on reducing the risk of events after AMI. 17,18 Second, the 
relatively low dose of β-blockers prescribed could be one of the reasons why β-blockers were not associated with better 
clinical outcomes in this study. The median dose of carvedilol was 5 mg per day in this study, which was lower than the 
dose previously reported. In the Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) trial, 
12.5-50 mg per day of carvedilol reduced all-cause mortality, cardiovascular-cause mortality, and reinfarction when 
given to patients with recent AMI and LVEF ≤ 40%. 19 Another study reported that Carvedilol produced dose-related 
reductions in mortality and hospitalization rate in patients with HF. 20 In the current analysis, use of higher-dose 
carvedilol (≥ 10 mg per day) was associated with a tendency of better clinical outcomes compared with use of lower-dose 
carvedilol (< 10 mg per day) in a risk-adjusted model (p = 0.08). However, the relatively low dose of β-blockers 
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prescribed in the study patients was probably attributed to the physical and racial differences of the study patients. 
Japanese patients had lower body weight compared to the American patients. The median body weight of the Japanese 
STEMI patients observed in the β group in this study was 62 (IQR: 54-70) kg, which is obviously lower compared to the 
American STEMI patients at 80 (IQR: 70-91) kg. 21 In addition, Asian patients are predisposed to hypotension and 
bradycardia with high-dose β-blockers. 22 According to investigations conducted in Japan, the approved dose of 
carvedilol for the treatment of hypertension, coronary artery disease, and HF is 2.5 to 20 mg per day for Japanese patients. 
23 Thus, the dose of β-blockers used in this study is thought to be reasonable for the study patients and it definitely 
reflected the real-world clinical practice in Japan. Third, we do not have information on which patients in the β group 
continued β-blockers during the years after discharge. Prescription of β-blockers at discharge might not be representative 
of long-term use of β-blockers after STEMI. However, previous studies reported that > 80% of patients continued to 
receive β-blockers 6 months after AMI. 24 In addition, patients not discharged on β-blockers are unlikely to be started on 
them as outpatients. 25 Forth, the current study did not have adequate power to assess outcomes in the subgroup with low 
LVEF. In this study, the use of β-blockers was not associated with better clinical outcomes in patients with low LVEF. 
The current result in the low-LVEF subgroup was inconsistent with the previous report from the j-Cypher registry that 
showed β-blockers after primary PCI were associated with reduced 3-year mortality in a subgroup of patients with low 
LVEF.6 It was also inconsistent with the PAMI study in which β-blockers were associated with lower 6-month mortality 
in patients with LVEF ≤ 50%. 5 Although all of these studies are observational and including relatively small number of 
patients with low LVEF, beneficial effect of β-blocker for STEMI patients with low LVEF has been reported in a 
large-scale randomized controlled trial in which about a half of the patients underwent reperfusion therapy mainly by 
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thrombolytic therapy.19 Finally, selection bias for use of β-blockers is inevitable in this type of observational study. 
Although we included potential confounders in the multivariable Cox proportional-hazards models and we tried to 
minimize the difference of baseline characteristics between patients in the β and no-β groups with propensity matching in 
the sensitivity analyses, we could not exclude influences of unmeasured confounders on clinical outcomes. The effect of 
β-blockers in patients with STEMI after successful PCI should be evaluated by a randomized controlled study with a 
large sample size. 
Conclusions 
In this study, oral β-blocker prescription at discharge was not associated with better cardiovascular outcomes in 
patients who underwent PCI after STEMI. Most of these patients had preserved LVEF and fair prognosis without 
β-blocker use. Large-scale randomized controlled trials are needed to evaluate the role of β-blocker therapy in these 
patients. 
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Figure Legends 
Figure 1. Study Flow Chart. 
CABG = coronary artery bypass surgery, PCI = percutaneous coronary intervention, and STEMI = ST-segment elevation 
myocardial infarction. 
 
Figure 2. Cardiac Death/MI Rates in the Study Population. 
Crude and adjusted cumulative incidence curves for cardiac death/MI among patients treated with or without β-blockers 
in the entire cohort (A), in the preserved LVEF subgroup (B), and in the low LVEF subgroup (C). 











Table 1. Baseline Clinical Characteristics, Procedural Characteristics and Baseline Medications in All 
Patients 
 β group No-β group p 
  N = 1,614 N = 2,078 value 
(A) Clinical characteristics    
Age (years) 65.8 ± 12.2 68.0 ± 12.1 < 0.0001 
   *Age ≥ 75 years 416 (25.8%) 668 (32.1%) < 0.0001 
*Male 1,255 (77.8%) 1,500 (72.2%) 0.0001 
Body weight (kg) 62.4 (54.2-70.0) ‡ 60.0 (53.0-68.0) ‡ < 0.0001† 
BMI 23.5 (21.5-25.9) 23.3 (21.3-25.3) 0.0008† 
   *BMI < 25.0 1,103 (68.3%) 1,529 (73.6%) 0.0005 
Onset-to-balloon time (hours) 4.1 (2.7-6.7) § 4.3 (2.9-7.6) § 0.002† 
    Onset-to-balloon time ≤ 6 hours 987 (70.4%) § 1,237 (67.3%) § 0.06 
Door-to-balloon time (hours) 1.5 (1.0-2.2) || 1.5 (1.0-2.2) || 0.24† 
*Anterior infarction 850 (52.7%) 955 (46.0%) < 0.0001 
*Hypertension 1,386 (85.9%) 1,521 (73.2%) < 0.0001 
Diabetes mellitus 494 (30.6%) 667 (32.1%) 0.33  
   *on insulin therapy 58 (3.6%) 92 (4.4%) 0.2  
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Table 1. Baseline Clinical Characteristics, Procedural Characteristics and Baseline Medications in All 
Patients (cont) 
*Current smoking 686 (42.5%) 850 (40.9%) 0.32 
*Heart failure 452 (28.0%) 556 (26.8%) 0.39 
*Shock at presentation 234 (14.5%) 268 (12.9%) 0.15  
*Multivessel disease 814 (50.4%) 1,048 (50.4%) 0.99 
*Mitral regurgitation grade 3/4 38 (2.4%) 53 (2.6%) 0.7  
LVEF (%) 52.4 ± 12.6 # 54.3 ± 12.2 # < 0.0001 
    LVEF ≤ 40% 228 (16.7%) # 222 (14.1%) # 0.04 
*Prior myocardial infarction 140 (8.7%) 177 (8.5%) 0.86 
*Prior stroke 121 (7.5%) 194 (9.3%) 0.04 
*Peripheral vascular disease 45 (2.8%) 60 (2.9%) 0.85 
*eGFR < 30ml/min, not on dialysis 50 (3.1%) 70 (3.4%) 0.64 
*Dialysis 24 (1.5%) 21 (1.0%) 0.19 
*Atrial fibrillation 163 (10.1%) 171 (8.2%) 0.04 
*Anemia (Hb < 11.0g/dl) 133 (8.2%) 172 (8.3%) 0.96 
*Platelet < 100*109/L 28 (1.7%) 27 (1.3%) 0.27 
*COPD 31 (1.9%) 94 (4.5%) < 0.0001 
*Liver cirrhosis 43 (2.7%) 46 (2.2%) 0.37 
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Table 1. Baseline Clinical Characteristics, Procedural Characteristics and Baseline Medications in All 
Patients (cont) 
*Malignancy 117 (7.3%) 175 (8.4%) 0.19 
(B) Procedural characteristics    
*DES use 480 (29.7%) 614 (29.5%) 0.89 
Number of target lesions 1 (1-2) 1 (1-2) 0.17† 
*Target of proximal LAD 947 (58.7%) 1,055 (50.8%) < 0.0001 
*Target of unprotected LMCA 42 (2.6%) 48 (2.3%) 0.56 
*Target of CTO 51 (3.2%) 58 (2.8%) 0.51 
*Target of bifurcation 414 (25.7%) 530 (25.5%) 0.92 
   *Side-branch stenting 45 (2.8%) 62 (3.0%) 0.72 
Total number of stents 1 (1-2) # 1 (1-2) # 0.42† 
Total stent length (mm) 25 (18-43) ** 24(18-42) ** 0.03† 
   *Total stent > 28mm 663 (44.3%) ** 799 (42.0%) ** 0.18  
Minimum stent size (mm) 3 (2.5-3.5) ** 3 (2.5-3.5) ** 0.42† 
   *Minimum stent size < 3.0mm 479 (32.0%) ** 589 (31.0%) ** 0.51 
(C) Discharge Medication    
Antiplatelet therapy    
    Thienopyridine 1,565 (97.0%) 1,998 (96.1%) 0.18 
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Table 1. Baseline Clinical Characteristics, Procedural Characteristics and Baseline Medications in All 
Patients (cont) 
       Ticlopidine 1,426 (88.4%) 1,838 (88.5%) 0.92 
       Clopidogrel 139 (8.6%) 159 (7.7%) 0.28 
    Aspirin 1,608 (99.6%) 2,064 (99.3%) 0.21 
   *Cilostazol 541 (33.5%) 770 (37.1%) 0.02 
Other medications    
   *Statins 1,034 (64.1%) 1,056 (50.8%) < 0.0001 
   *ACE-I/ARB 1,342 (83.2%) 1,451 (69.8%) < 0.0001 
   *Nitrates 421 (26.1%) 696 (33.4%) < 0.0001 
   *Calcium channel blockers 333 (20.6%) 429 (20.6%) 0.99 
   *Nicorandil 488 (30.2%) 600 (28.9%) 0.36 
   *Warfarin 238 (14.8%) 192 (9.2%) < 0.0001 
   *Proton pump inhibitors 588 (36.4%) 697 (33.5%) 0.06 
   *H2-blockers 533 (33.0%) 774 (37.2%) 0.007  
Variables are mean ± SD, n (%), or median (IQR). *Clinically relevant risk adjusting variables selected for 
multivariable Cox proportional-hazards model for β-blocker therapy. 
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† Wilcoxon p value. 
‡ Values were missing for body weight (kg) in 107 patients, 30 in β group and 77 in no-β group. 
§ Values were missing for onset-to-balloon time (hours) in 453 patients, 212 in β group and 241 in no-β group. 
|| Values were missing for door-to-balloon time (hours) in 495 patients, 240 in β group and 255 in no-β group. 
# Values were missing for LVEF in 748 patients, 249 in β group and 499 in no-β group. 
** Exclude 292 patients without stent implantation, 117 in β group and 175 in no-β group. 
ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI = body mass 
index, COPD = chronic obstructive pulmonary disease, DES = drug-eluting stent, CTO = chronic total 
occlusion, eGFR = estimated glomerular filtration rate, H2-blocker = histamine type2 receptor blocker, LAD = 





















(A) All patients N = 1,614 N = 2,078     
Cardiac death/MI 110 (7.6%) 118 (6.2%) 0.11  
1.43 
[1.06-1.94]  0.01 
All-cause death 99 (7.5%) 150 (8.2%) 0.18  
0.99 
[0.73-1.34]  0.96 
Cardiac death 50 (3.7%) 62 (3.3%) 0.86  
1.44 
[0.91-2.28]  0.11 
MI 73 (4.9%) 63 (3.3%) 0.01  
1.55 
[1.07-2.27]  0.02 
Hospitalization for HF 104 (7.2%) 105 (5.6%) 0.06  
1.68 
[1.21-2.33] 0.001 
(B) Preserved LVEF N = 1,137 N = 1,357      




Table 2. Crude Event Rates and Adjusted Hazard Ratio Through 3 Years (cont) 
All-cause death 46 (4.9%) 71 (6.0%) 0.17 
0.87 
[0.56-1.37] 0.57 
Cardiac death 21 (2.1%) 27 (2.3%) 0.76 
1.40 
[0.67-2.92] 0.36 
MI 49 (4.6%) 49 (3.8%) 0.32 
1.19 
[0.77-1.85] 0.42 
Hospitalization for HF 54 (5.4%) 48 (3.9%) 0.09 
1.82 
[1.12-2.96] 0.01 
(C) Low LVEF N = 222 N = 228     
Cardiac death/MI 25 (12.5%) 20 (9.8%) 0.44  
1.75 
[0.69-4.47]  0.24 
All-cause death 29 (15.5%) 33 (17.0%) 0.35  
1.81 
[0.76-4.34]  0.17 
Cardiac death 19 (10.3%) 18 (8.9%) 0.86  
2.20 
[0.65-7.41] 0.20 
MI 11 (5·2%)  4 (2.0%) 0.04  ― ―* 
Hospitalization for HF 34 (16.0%) 34 (17.1%) 0.63  
1.26 
[0.62-2.53]  0.51 
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Incidences at 3 years were estimated by the Kaplan-Meier method. 
* Adjusted HR of MI in low LVEF group could not be evaluated. 
CI = confidence interval, HF = heart failure, HR = hazard ratio, LVEF = left ventricular ejection fraction, and 
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Supplemental Table 1. Multivariable Cox Proportional-hazards Model for 3-year Risk of 
Cardiac Death/MI 
 Hazard Ratio 95% CI  p value 
 
β-blockers 1.43 1.06-1.94 0.01 
Age ≥ 75 years 2.07 1.51-2.86 < 0.0001 
Male 0.97 0.69-1.37 0.87 
BMI < 25.0 1.17 0.84-1.65 0.35 
Anterior infarction 1.25 0.83-1.88 0.28 
Hypertension 1.18 0.81-1.71 0.38 
DM on insulin therapy 1.45 0.84-2.50 0.18 
Current smoking 1.37 1.00-1.86 0.04 
Heart failure 1.17 0.80-1.73 0.42 
Shock at presentation 1.25 0.80-1.96 0.33 
Multivessel disease 1.26 0.92-1.73 0.15 
Mitral regurgitation grade 3/4 0.84 0.38-1.87 0.66 
Prior myocardial infarction 1.64 1.09-2.48 0.01 
Prior stroke 1.27 0.82-1.97 0.28 
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Supplemental Table 1. Multivariable Cox Proportional-hazards Model for 3-year Risk of 
Cardiac Death/MI (cont) 
 
Peripheral vascular disease 1.48 0.80-2.73 0.2 
eGFR < 30ml/min, not on dialysis 1.83 1.07-3.15 0.02 
Dialysis 1.97 0.75-5.20 0.16 
Atrial fibrillation 1.14 0.73-1.79 0.56 
Anemia (Hb < 11.0g/dl) 1.10 0.71-1.70 0.66 
Platelet < 100*109/L 2.23 1.13-4.41 0.02 
COPD 2.39 1.35-4.23 0.002 
Liver cirrhosis 0.99 0.47-2.06 0.97 
Malignancy 1.37 0.91-2.05 0.13 
DES use 0.62 0.40-0.96 0.03 
Target of proximal LAD 1.09 0.71-1.67 0.69 
Target of unprotected LMCA 1.42 0.70-2.88 0.33 
Target of CTO 1.68 0.90-3.11 0.1 
Target of bifurcation 0.92 0.64-1.31 0.63 
Side-branch stenting 1.38 0.71-2.68 0.33 
Total stent > 28mm 1.40 1.01-1.93 0.04 
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Supplemental Table 1. Multivariable Cox Proportional-hazards Model for 3-year Risk of 
Cardiac Death/MI (cont) 
Minimum stent size < 3.0mm 1.16 0.83-1.61 0.39 
Cilostazol 1.00 0.64-1.56 0.99 
Statins 0.81 0.60-1.09 0.15 
ACE-I/ARB 0.60 0.43-0.83 0.001 
Nitrates 0.86 0.60-1.23 0.4 
Calcium channel blockers 0.88 0.62-1.25 0.47 
Nicorandil 0.97 0.68-1.38 0.85 
Warfarin 1.18 0.76-1.84 0.45 
Proton pump inhibitors 1.50 1.06-2.12 0.02 
H2-blockers 1.16 0.80-1.68 0.43 
ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI = body 
mass index, CI = confidence interval, COPD = chronic obstructive pulmonary disease, CTO = 
chronic total occlusion, DES = drug-eluting stent, eGFR = estimated glomerular filtration rate, 
H2-blocker = histamine type2 receptor blocker, LAD = left anterior descending coronary artery, 
LMCA = left main coronary artery, and MI = myocardial infarction. 
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Supplemental Table 2. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Preserved LVEF 
 β group No-β group p 
  N = 1137 N = 1357 value 
 
(A) Clinical characteristics    
Age (years) 65.3 ± 11.9 67.4 ± 12.1 < 0.0001 
   Age ≥ 75 years 266 (23.4%) 398 (29.3%) 0.0008 
Male 885 (77.8%) 972 (71.6%) 0.0004 
Body weight (kg) 63 (55-70) ‡ 60 (53-68) ‡ < 0.0001 
BMI 23.6 (21.8-25.9) 23.4 (21.3-25.4) 0.0008* 
   BMI < 25.0 765 (67.3%) 986 (72.7%) 0.003 
Onset-to-balloon time (hours) 4 (2.7-6.6) § 4.2 (2.9-7.5) § 0.06* 
   Onset-to-balloon time ≤ 6 hours 687 (70.8%) § 803 (67.8%) § 0.13 
Door-to-balloon time (hours) 1.5 (1.0-2.2) || 1.5 (1.0-2.2) || 0.95* 
Anterior infarction 568 (50.0%) 584 (43.0%) 0.0006 
Hypertension 983 (86.5%) 1000 (73.7%) < 0.0001 
Diabetes mellitus 335 (29.5%) 431 (31.8%) 0.21 
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Supplemental Table 2. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Preserved LVEF (cont) 
   on insulin therapy 35 (3.1%) 59 (4.4%) 0.09 
Current smoking 491(43.2%) 554 (40.8%) 0.23 
Heart failure 248 (21.8%) 296 (21.8%) 0.99 
Shock at presentation 120 (10.6%) 153 (11.3%) 0.56 
Multivessel disease 565 (49.7%) 673 (49.6%) 0.96 
Mitral regurgitation grade 3/4 20 (1.8%) 37 (2.7%) 0.1 
LVEF (%) 55 (49-63) 57 (50-65) 0.0002* 
Prior myocardial infarction 78 (6.9%) 108 (8.0%) 0.29 
Prior stroke 77 (6.8%) 106 (7.8%) 0.32 
Peripheral vascular disease 30 (2.6%) 40 (3.0%) 0.64 
eGFR < 30 ml/min, not on dialysis 26 (2.3%) 35 (2.6%) 0.63 
Dialysis 13 (1.1%) 11 (0.8%) 0.39 
Atrial fibrillation 109 (9.6%) 104 (7.7%) 0.08 
Anemia (Hb < 11.0g/dl) 87 (7.7%) 98 (7.2%) 0.68 
Platelet < 100*109/L 21 (1.9%) 14 (1.0%) 0.08 
COPD 25 (2.2%) 66 (4.9%) < 0.0001 
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Supplemental Table 2. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Preserved LVEF (cont) 
 
Liver cirrhosis 30 (2.6%) 32 (2.4%) 0.65 
Malignancy 74 (6.5%) 112 (8.3%) 0.09 
(B) Procedural characteristics    
DES use 341 (30.0%) 410 (30.2%) 0.9  
Number of target lesions 1 (1-2) 1 (1-2) 0.21* 
Target of proximal LAD 647 (56.9%) 659 (48.6%) < 0.0001 
Target of unprotected LMCA 26 (2.3%) 27 (2.0%) 0.6  
Target of CTO 31 (2.7%) 37 (2.7%) 0.99 
Target of bifurcation 292 (25.7%) 323 (23.8%) 0.27 
Side-branch stenting 31 (2.7%) 37 (2.7%) 0.99 
Total number of stents 1 (1-2) || 1 (1-2) || 0.65* 
Total stent length (mm) 25 (18-43) # 24 (18-43) # 0.17* 
   Total stent > 28mm 465 (43.7%) # 526 (42.0%) # 0.39 
Minimum stent size (mm) 3 (2.5-3.5) # 3 (2.5-3.5) # 0.61* 
   Minimum stent size < 3.0mm 332 (31.2%) # 407 (32.5%) # 0.52 
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Supplemental Table 2. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Preserved LVEF (cont) 
 
(C) Discharge Medication    
Antiplatelet therapy    
   Thienopyridine 1110 (97.6%) 1312 (96.7%) 0.15 
      Ticlopidine 1013 (89.1%) 1207 (88.9%) 0.47 
      Clopidogrel 97 (8.5%) 104 (7.7%) 0.47 
   Aspirin 1133 (99.6%) 1351 (99.5%) 0.76† 
   Cilostazol 343 (30.2%) 434 (32.0%) 0.32 
Other medications    
   Statins 753 (66.2%) 720 (53.1%) < 0.0001 
   ACE-I/ARB 981 (86.3%) 997 (73.5%) < 0.0001 
   Nitrates 306 (26.9%) 448 (33.0%) 0.0009 
   Calcium channel blockers 247 (21.7%) 294 (21.7%) 0.97 
   Nicorandil 329 (28.9%) 366 (27.0%) 0.27 
   Warfarin 151 (13.3%) 108 (8.0%) < 0.0001 
   Proton pump inhibitors 422 (37.1%) 444 (32.7%) 0.02 
   H2-blockers 381 (33.5%) 496 (36.6%) 0.11 
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Supplemental Table 2. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Preserved LVEF (cont) 
Variables are mean ± SD, n (%), or median (IQR). 
*Wilcoxon p value. † Fisher p value. 
‡ Values were missing for body weight (kg) in 48 patients, 15 in beta group and 33 in no-beta 
group. 
§ Values were missing for onset-to-balloon time (hours) in 338 patients, 166 in beta group 
and 172 in no-beta group. 
|| Values were missing for door-to-balloon time (hours) in 364 patients, 184 in beta group and 
180 in no-beta group. 
# Exclude 176 patients without stent implantation, 73 in beta group and 103 in no-beta group. 
ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI 
= body mass index, COPD = chronic obstructive pulmonary disease, CTO = chronic total 
occlusion, DES = drug-eluting stent, eGFR = estimated glomerular filtration rate, H2-blocker 
= histamine type2 receptor blocker, LAD = left anterior descending coronary artery, LMCA = 
left main coronary artery, and LVEF = left ventricular ejection fraction. 
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Supplemental Table 3. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Low LVEF 
 β group No-β group p 
  N = 228 N = 222 value 
 
(A) Clinical characteristics    
Age (years) 67.0 ± 12.4 70.5 ± 11.9 0.002 
   Age ≥ 75 years 71 (31.1%) 90 (40.5%) 0.03 
Male 179 (78.5%) 160 (72.1%) 0.11 
Body weight (kg) 60 (52-69) ‡ 59 (50-66) ‡ 0.07 
BMI 22.9 (20.7-25.1) 22.9 (20.5-24.5) 0.38* 
   BMI < 25.0 170 (74.6%) 181 (81.5%) 0.07 
Onset-to-balloon time (hours) 4.2 (2.7-7.0) § 5.1 (1.3-10.1) § 0.002* 
   Onset-to-balloon time ≤6 hours 136 (68.0%) § 115 (58.1%) § 0.04 
Door-to-balloon time (hours)§ 1.6 (1.0-2.4) || 1.6 (1.0-2.3) || 0.59* 
Anterior infarction 152 (66.7%) 159 (71.6%) 0.25 
Hypertension 192 (84.2%) 167 (75.2%) 0.01 
Diabetes mellitus 83 (36.4%) 69 (31.1%) 0.23 
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Supplemental Table 3. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Low LVEF (cont) 
   on insulin therapy 12 (5.3%) 11 (5.0%) 0.88 
Current smoking 94 (41.3%) 84 (37.8%) 0.46 
Heart failure 122 (53.5%) 113 (50.9%) 0.57 
Shock at presentation 65 (28.5%) 42 (18.9%) 0.01 
Multivessel disease 119 (52.2%) 117 (52.7%) 0.91 
Mitral regurgitation grade 3/4 14 (6.1%) 10 (4.5%) 0.43 
LVEF (%)| 35 (30-38) 36 (30.8-39) 0.07* 
Prior myocardial infarction 33 (14.5%) 34 (15.3%) 0.8 
Prior stroke 22 (9.7%) 32 (14.4%) 0.11 
Peripheral vascular disease 9 (4.0%) 10 (4.5%) 0.76 
eGFR < 30 ml/min, not on dialysis 16 (7.0%) 12 (5.4%) 0.47 
Dialysis 6 (2.6%) 6 (2.7%) 0.96 
Atrial fibrillation 31 (13.6%) 24 (10.8%) 0.36 
Anemia (Hb < 11.0g/dl) 24 (10.5%) 28 (12.6%) 0.48 
Platelet < 100*109/L 5 (2.2%) 8 (3.6%) 0.36 
COPD 3 (1.3%) 15 (6.8%) 0.003 
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Supplemental Table 3. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Low LVEF (cont) 
 
Liver cirrhosis 7 (3.1%) 4 (1.8%) 0.38 
Malignancy 19 (8.3%) 22 (9.9%) 0.56 
(B) Procedural characteristics    
DES use 80 (35.1%) 81 (36.5%) 0.75 
Number of target lesions 1 (1-2) 1 (1-2) 0.14* 
Target of proximal LAD 159 (69.7%) 159 (71.6%) 0.66 
Target of unprotected LMCA 11 (4.8%) 8 (3.6%) 0.51 
Target of CTO 8 (3.5%) 10 (4.5%) 0.58 
Target of bifurcation 63 (27.6%) 76 (34.2%) 0.12 
   Side-branch stenting 4 (1.8%) 8 (3.6%) 0.21 
Total number of stents 1 (1-2) # 1 (1-2) # 0.09* 
Total stent length (mm) 28 (20-44) # 24 (18-40.3) # 0.07* 
   Total stent > 28mm 98 (45.6%) # 80 (38.8%) # 0.16 
Minimum stent size (mm) 3 (2.5-3.5) # 3 (2.8-3.5) # 0.37* 
   Minimum stent size < 3.0mm 79 (36.7%) # 55 (26.7%) # 0.02 
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Supplemental Table 3. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Low LVEF (cont) 
  
(C) Discharge Medication    
Antiplatelet therapy    
   Thienopyridine 221 (96.9%) 214 (96.4%) 0.75 
      Ticlopidine 200 (87.7%) 204 (91.9%) 0.04 
      Clopidogrel 21 (9.2%) 10 (4.5%) 0.04 
   Aspirin 226 (99.1%) 221 (99.6%) 1† 
   Cilostazol 72 (31.6%) 98 (44.1%) 0.005 
Other medications    
   Statins 133 (58.3%) 97 (43.7%) 0.001 
   ACE-I/ARB 185 (81.1%) 163 (73.4%) 0.05 
   Nitrates 59 (25.9%) 75 (33.8%) 0.06 
   Calcium channel blockers 44 (19.3%) 44 (19.8%) 0.88 
   Nicorandil 57 (25.0%) 54 (24.3%) 0.86 
   Warfarin 63 (27.6%) 43 (19.4%) 0.03 
   Proton pump inhibitors 98 (43.0%) 80 (36.0%) 0.13 
   H2-blockers 65 (28.5%) 80 (36.0%) 0.08 
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Supplemental Table 3. Baseline Clinical Characteristics, Procedural Characteristics and 
Baseline Medications in Patients with Low LVEF (cont) 
Variables are mean ± SD, n (%), or median (IQR). 
*Wilcoxon p value. † Fisher p value. 
‡ Values were missing for body weight (kg) in 21 patients, 5 in beta group and 16 in no-beta 
group. 
§ Values were missing for onset-to-balloon time (hours) in 52 patients, 28 in beta group and 
24 in no-beta group. 
|| Values were missing for door-to-balloon time (hours) in 64 patients, 37 in beta group and 27 
in no-beta group. 
# Exclude 29 patients without stent implantation, 13 in beta group and 16 in no-beta group. 
ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI 
= body mass index, COPD = chronic obstructive pulmonary disease, CTO = chronic total 
occlusion, DES = drug-eluting stent, eGFR = estimated glomerular filtration rate, H2-blocker 
= histamine type2 receptor blocker, LAD = left anterior descending coronary artery, LMCA = 
left main coronary artery, and LVEF = left ventricular ejection fraction. 
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Supplemental Table 4. Baseline Clinical Characteristics According to Doses of Carvedilol 
 
Carvedilol  
≥ 10 mg per day  
Carvedilol  
< 10 mg per day  p 
  N = 385 N = 1,071 value 
 
Clinical characteristics    
Age (years) 63.8 ± 11.8 66.5 ± 12.4 < 0.0001 
   *Age ≥ 75 years 82 (21.3%) 297 (27.7%) 0.01 
*Male 320 (83.1%) 814 (76.0%) 0.003 
Body weight (kg) 64 (57-72) 62 (53-70) < 0.0001 
BMI 24.2 (22.0-26.6) 23.4 (21.3-25.5) < 0.0001† 
   *BMI < 25.0 242 (62.9%) 760 (71.0%) 0.003 
Onset-to-balloon time (hours) 4.1 (2.8-6.5) 4.1 (2.7-6.7) 0.66† 
    Onset-to-balloon time ≤ 6 hours 244 (72.0%) ‡ 649 (70.5%) ‡ 0.06 
Door-to-balloon time (hours) 1.1 (0.8-1.6) § 1 (0.8-1.5) § 0.06† 
*Anterior infarction 196 (50.9%) 583 (54.4%) 0.23 
*Hypertension 347 (90.1%) 899 (83.9%) 0.003 
Diabetes mellitus 136 (35.3%) 311 (29.0%) 0.02 
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Supplemental Table 4. Baseline Clinical Characteristics According to Doses of Carvedilol 
(cont) 
 
   *on insulin therapy 14 (3.6%) 36 (3.4%) 0.8 
*Current smoking 169 (43.9%) 464 (43.3%) 0.84 
*Heart failure 92 (23.9%) 322 (30.1%) 0.02 
*Shock at presentation 40 (10.4%) 174 (16.2%) 0.005 
*Multivessel disease 205 (53.2%) 525 (49.0%) 0.15 
*Mitral regurgitation grade 3/4 8 (2.1%) 25 (2.3%) 0.77 
LVEF (%) 54 (47-62) || 52 (43-62) || 0.001† 
    LVEF ≤ 40% 37 (11.4%) || 169 (18.3%) || 0.003 
*Prior myocardial infarction 32 (8.3%) 92 (8.6%) 0.86 
*Prior stroke 37 (9.6%) 73 (6.8%) 0.07 
*Peripheral vascular disease  12 (3.1%) 32 (3.0%) 0.89 
*eGFR < 30 ml/min, not on dialysis 17 (4.4%) 27 (2.5%) 0.06 
*Dialysis 4 (1.0%) 18 (1.7%) 0.37 
*Atrial fibrillation 36 (9.4%) 107 (10.0%) 0.71 
*Anemia (Hb < 11.0g/dl) 25 (6.5%) 98 (9.2%) 0.1 
*Platelet < 100*109/L 4 (1.0%) 18 (1.7%) 0.37 
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Supplemental Table 4. Baseline Clinical Characteristics According to Doses of Carvedilol 
(cont) 
*COPD 2 (0.5%) 26 (2.4%) 0.01 
*Liver cirrhosis 6 (1.6%) 34 (3.2%) 0.09 
*Malignancy 22 (5.7%) 84 (7.8%) 0.16 
Variables are mean ± SD, n (%), or median (IQR). *Clinically relevant risk variables selected for 
multivariable Cox proportional-hazards model for doses of carvedilol. 
† Wilcoxon p value. 
‡ Values were missing for onset-to-balloon time (hours) in 196 patients, 46 in high dose group and 
150 in low dose group. 
§ Values were missing for door-to-balloon time (hours) in 220 patients, 51 in high dose group and 
169 in low dose group. 
|| Values were missing for LVEF in 207 patients, 59 in high dose group and 148 in low dose group. 
BMI = body mass index, COPD = chronic obstructive pulmonary disease, and eGFR = estimated 




Supplemental Table 5. Crude Event Rates and Adjusted Hazard Ratio Through 3 Years 
According to Doses of Carvedilol 
 
Carvedilol  
≥ 10 mg 
per day  
Carvedilol  
< 10 mg 





 N = 385 N = 1,071 value [95%CI] value 
Cardiac death/MI 17 (4.7%) 85 (8.9%) 0.02 
0.65 
[0.38-1.05] 0.08  
All-cause death 15 (4.6%) 74 (8.5%) 0.05 
0.82 
[0.48-1.38] 0.48  
Cardiac death 6 (1.8%) 40 (4.6%) 0.02 
0.57 
[0.23-1.24] 0.16  
MI 12 (3.3%) 55 (5.6%) 0.13  
0.65 
[0.34-1.14] 0.13  
Hospitalization for HF 21 (5.9%) 71 (7.5%) 0.68  
1.10 
[0.56-2.04] 0.76  
Variables are n (%). Incidences at 3 years were estimated by the Kaplan-Meier method. 
CI = confidence interval, HF = heart failure, HR = hazard ratio, LVEF = left ventricular 






Supplemental Table 6. Baseline Clinical Characteristics in Propensity Score Matched 
Population 
 β group No-β group p 
 N = 1,614 N = 1,614 value 
 
Age ≥ 75 years 416 (25.8%) 392 (24.3%) 0.32 
Male 1,255 (77.8%) 1,243 (77.0%) 0.61 
BMI < 25.0 1,103 (68.3%) 1,093 (67.7%) 0.7 
Anterior infarction 850 (52.7%) 847 (52.5%) 0.91 
Hypertension 1,386 (85.9%) 1,388 (86.0%) 0.91 
DM on insulin therapy 58 (3.6%) 60 (3.7%) 0.2 
Heart failure 452 (28.0%) 398 (24.7%) 0.03 
Shock at presentation 234 (14.5%) 187 (11.6%) 0.01 
Multivessel disease 814 (50.4%) 856 (53.0%) 0.13 
Prior myocardial infarction 140 (8.7%) 141 (8.7%) 0.95 
Prior stroke 121 (7.5%) 135 (8.4%) 0.36 
Peripheral vascular disease 45 (2.8%) 33 (2.0%) 0.16 
Dialysis 24 (1.5%) 28 (1.7%) 0.57 
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Supplemental Table 6. Baseline Clinical Characteristics in Propensity Score Matched 
Population (cont) 
Atrial fibrillation 163 (10.1%) 183 (11.3%) 0.25 
COPD 31 (1.9%) 21 (1.3%) 0.16 
Liver cirrhosis 43 (2.7%) 41 (2.5%) 0.82 
Malignancy 117 (7.3%) 119 (7.4%) 0.89 
Target of proximal LAD 947 (58.7%) 966 (59.9%) 0.49 
Target of unprotected LMCA 42 (2.6%) 30 (1.9%) 0.15 
Statins 1,034 (64.1%) 1,006 (62.3%) 0.3 
ACE-I/ARB 1,342 (83.2%) 1,243 (83.2%) 0.96 
Nitrates 421 (26.1%) 405 (25.1%) 0.51 
Calcium channel blockers 333 (20.6%) 335 (20.8%) 0.93 
Nicorandil 488 (30.2%) 513 (31.8%) 0.34 
Variables are n (%). ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor 
blocker, BMI = body mass index, COPD = chronic obstructive pulmonary disease, DM = diabetes 
mellitus, LAD = left anterior descending coronary artery, and LMCA = left main coronary artery. 
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Supplemental Table 7. Event Rates Through 3 Years in Propensity Score Matched Population 
 
β group 
N = 1,614 
No-β group 
N = 1,614 
p 
value 











All-cause death 0.23 
Cardiac death 0.46 
MI 0.22 
Hospitalization for HF < 0.0001 
Incidences at 3 years were estimated by the Kaplan-Meier method. 
HF = heart failure and MI = myocardial infarction. 
 
 
 
 
